<i>Retracted:</i> KIF20A silence inhibits the migration, invasion and proliferation of non‐small cell lung cancer and regulates the JNK pathway

Xie, Feng; He, Chengyan; Gao, Shen; Yang, Zunhua; Li, Lihong; Liao, Qiao; Fang, Ling

doi:10.1111/1440-1681.13183

Cited by 21 publications

(19 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies have showed that KIF20A high expression was linked to poor survival of HCC patients [ 32 – 34 ], which is consistent with our findings. Our in vitro functional results revealed that KIF20A silence attenuated the proliferation and increased capsase-3 and -9 activities of HCC cells, consistent with studies showing that KIF20A promoted cell proliferation in pancreatic [ 35 ], ovarian [ 36 ], bladder [ 37 ] and lung cancer [ 38 ]; caspase-3 and -9 are two key mediators in the apoptotic signaling pathways, and our results may imply that KIF20A knockdown repressed HCC cell proliferation cells via enhancing activities of cell apoptotic signaling pathway. Actions of KIF20A in the chemo-sensitivity of cancer cells have not been reported.…”

Section: Discussionsupporting

confidence: 88%

Low expression of KIF20A suppresses cell proliferation, promotes chemosensitivity and is associated with better prognosis in HCC

Qiu

et al. 2021

Aging

View full text Add to dashboard Cite

This study analysed the microarray datasets from Gene Expression Omnibus (GEO) database, and aimed to identify novel potential hub genes associated with the progression of HCC via bioinformatics analysis and experimental validation. The common differentially expressed genes (DEGs) from five GEO datasets were screened using GEO2R tool. The expression and survival analysis of hub genes in HCC were performed using Gene Expression Profiling Interactive Analysis, UALCAN and Kaplan-Meier plotter tools. In vitro functional assays were used to determine the caspase-3, -9, cell proliferation and chemo-sensitivity of HCC cells. A total of 177 common DEGs were identified between normal liver and HCC tissues among these datasets. Functional enrichment and PPI network analysis identified 22 hub genes from the common DEGs. The mRNA expression of 22 hub genes was all significantly up-regulated in HCC tissues compared to that in normal liver tissues. Further survival analysis showed that 10 hub genes predicted poor prognosis of patients with HCC. More importantly, the in vitro functional studies demonstrated that KIF20A knockdown suppressed the HCC cell proliferation and promoted the chemosensitivity of HCC cells to cisplatin and sorafenib. In conclusion, the present study identified a total of 177 common DEGs among 5 GEO microarray datasets and found that 10 hub genes could predict the poor prognosis of patients with HCC using the comprehensive bioinformatics analysis. Furthermore, KIF20A silence suppressed cell proliferation and enhanced chemosensitivity in HCC cells. Further studies may be required to determine the mechanistic role of these hub genes in HCC progression.

show abstract

Section: Discussionsupporting

confidence: 88%

Low expression of KIF20A suppresses cell proliferation, promotes chemosensitivity and is associated with better prognosis in HCC

Qiu

et al. 2021

Aging

View full text Add to dashboard Cite

show abstract

“…They have undergone several clinical trials but there are no data available for NSCLC yet. Studies have also shown that KIF20A knockdown reduced the proliferation, invasion, and migration of NSCLC cells via regulation of JNK signaling pathways [45]. Microarray analysis based study has identified that Forkhead box M1 (FOXM1) positively regulates the expression of KIF20A and upregulation of FOXM1 is associated with several normal and transformed cells of hepatocellular and skin basal cell carcinoma [42].…”

Section: Discussionmentioning

confidence: 99%

Unravelling the Role of miR-20b-5p, CCNB1, HMGA2 and E2F7 in Development and Progression of Non-Small Cell Lung Cancer (NSCLC)

Arora

Singh

Rahmani

et al. 2020

Biology

View full text Add to dashboard Cite

Lung cancer is a prime cause of worldwide cancer deaths, with non-small cell lung cancer (NSCLC) as a frequent subtype. Surgical resection, chemotherapy are the currently used treatment methods. Delayed detection, poor prognosis, tumor heterogeneity, and chemoresistance make them relatively ineffective. Genomic medicine is a budding aspect of cancer therapeutics, where miRNAs are impressively involved. miRNAs are short ncRNAs that bind to 3’UTR of target mRNA, causing its degradation or translational repression to regulate gene expression. This study aims to identify important miRNA-mRNA-TF interactions in NSCLC using bioinformatics analysis. GEO datasets containing mRNA expression data of NSCLC were used to determine differentially expressed genes (DEGs), and identification of hub genes-BIRC5, CCNB1, KIF11, KIF20A, and KIF4A (all functionally enriched in cell cycle). The FFL network involved, comprised of miR-20b-5p, CCNB1, HMGA2, and E2F7. KM survival analysis determines that these components may be effective prognostic biomarkers and would be a new contemplation in NSCLC therapeutics as they target cell cycle and immunosurveillance mechanisms via HMGA2 and E2F7. They provide survival advantage and evasion of host immune response (via downregulation of cytokines-IL6, IL1R1 and upregulation of chemokines-CXCL13, CXCL14) to NSCLC. The study has provided innovative targets, but further validation is needed to confirm the proposed mechanism.

show abstract

“…Among the 5-gene signature identified in this study, it is known that KIF20A (Kinesin family member 20A) is involved in spindle formation during cell division ( 28 ), and Keratin 6A (KRT6A), a member of keratin proteins family, mainly lead to epidermalization of squamous epithelium. Both KIF20A and KRT6A were reported to be highly expressed in tumor tissues and associated with poor prognosis in multiple cancers, such as prostate, breast, gastric and pancreatic cancers ( 29 – 32 ). Moreover, they could also promote proliferation and migration, as well as inhibit apoptosis in lung cancer ( 33 ).…”

Section: Discussionmentioning

confidence: 99%

Identification of Prognostic Signature and Gliclazide as Candidate Drugs in Lung Adenocarcinoma

et al. 2021

View full text Add to dashboard Cite

BackgroundLung adenocarcinoma (LUAD) is the most common pathological type of lung cancer, with high incidence and mortality. To improve the curative effect and prolong the survival of patients, it is necessary to find new biomarkers to accurately predict the prognosis of patients and explore new strategy to treat high-risk LUAD.MethodsA comprehensive genome-wide profiling analysis was conducted using a retrospective pool of LUAD patient data from the previous datasets of Gene Expression Omnibus (GEO) including GSE18842, GSE19188, GSE40791 and GSE50081 and The Cancer Genome Atlas (TCGA). Differential gene analysis and Cox proportional hazard model were used to identify differentially expressed genes with survival significance as candidate prognostic genes. The Kaplan–Meier with log-rank test was used to assess survival difference. A risk score model was developed and validated using TCGA-LUAD and GSE50081. Additionally, The Connectivity Map (CMAP) was used to predict drugs for the treatment of LUAD. The anti-cancer effect and mechanism of its candidate drugs were studied in LUAD cell lines.ResultsWe identified a 5-gene signature (KIF20A, KLF4, KRT6A, LIFR and RGS13). Risk Score (RS) based on 5-gene signature was significantly associated with overall survival (OS). Nomogram combining RS with clinical pathology parameters could potently predict the prognosis of patients with LUAD. Moreover, gliclazide was identified as a candidate drug for the treatment of high-RS LUAD. Finally, gliclazide was shown to induce cell cycle arrest and apoptosis in LUAD cells possibly by targeting CCNB1, CCNB2, CDK1 and AURKA.ConclusionThis study identified a 5-gene signature that can predict the prognosis of patients with LUAD, and Gliclazide as a potential therapeutic drug for LUAD. It provides a new direction for the prognosis and treatment of patients with LUAD.

show abstract

Retracted: KIF20A silence inhibits the migration, invasion and proliferation of non‐small cell lung cancer and regulates the JNK pathway

Cited by 21 publications

References 29 publications

Low expression of KIF20A suppresses cell proliferation, promotes chemosensitivity and is associated with better prognosis in HCC

Low expression of KIF20A suppresses cell proliferation, promotes chemosensitivity and is associated with better prognosis in HCC

Unravelling the Role of miR-20b-5p, CCNB1, HMGA2 and E2F7 in Development and Progression of Non-Small Cell Lung Cancer (NSCLC)

Identification of Prognostic Signature and Gliclazide as Candidate Drugs in Lung Adenocarcinoma

Contact Info

Product

Resources

About